Single-domain antibody-based and linker-free bispecific antibodies targeting fcgriii induce potent antitumor activity without recruiting regulatory T cells

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1481-1491

  Rozan, Caroline ^a,b,c,d   Cornillon, Amelie ^a,b,c,d   Petiard, Corinne ^a,b,c,d   Chartier, Martine ^a,b,c,d   Behar, Ghislaine ^a,b,c,d   Boix, Charlotte ^b,e,f,g   Kerfelec, Brigitte ^a,b,c,d   Robert, Bruno ^b,h   Pelegrin, Andre ^b,h   Chames, Patrick ^a,b,c,d   Teillaud, Jean Luc ^b,e,f,g   Baty, Daniel ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD16 ANTIGEN; IMMUNOGLOBULIN G1; NANOBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN POLYMORPHISM; PROTEIN TARGETING; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CYTOKINES; DRUG STABILITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MICE; NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PROTEIN STABILITY; RECEPTORS, IGG; SINGLE-DOMAIN ANTIBODIES; T-LYMPHOCYTES, REGULATORY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882241230     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1012     Document Type: Article

References (51)

1. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33.
2. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012;2:676-90.
3. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective. Drug Discov Today 2007;12:898-910.
4. Glorius P, Baerenwaldt A, Kellner C, Staudinger M, Dechant M, Stauch M, et al. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. Leukemia 2013;27:190-201.
5. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80.
6. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
7. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96.
8. Siberil S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007;62: 26-33.
9. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278: 3466-73.
10. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008;140: 635-43.
11. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006;43:1183-93.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6.
13. Shields RL,Namenuk AK, Hong K,MengYG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcgammaRI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001;276: 6591-604.
14. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005-10.
15. Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E, et al. Molecular aspects of human FcgammaR interactions with IgG: Functional and therapeutic consequences. Immunol Lett 2006;106:111-8.
16. Michon J, Moutel S, Barbet J, Romet-Lemonne JL, Deo YM, Fridman WH, et al. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-FcgammaRI bispecific antibody. Blood 1995;86:1124-30.
17. Muller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007;9:319-26.
18. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15.
19. Chames P, Baty D. Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 2009;12:276-83.
20. Chames P, Baty D. Bispecific antibodies for cancer therapy: The light at the end of the tunnel? MAbs 2009;1:539-47.
21. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cellengaging antibody. Science 2008;321:974-7.
22. Fischer N, Leger O. Bispecific antibodies: Molecules that enable novel therapeutic strategies. Pathobiology 2007;74:3-14.
23. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-8.
24. Su C, Nguyen VK, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. Mol Biol Evol 2002;19:205-15.
25. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002;11:500-15.
26. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009;284:3273-84.
27. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. Camel singledomain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001;276:7346-50.
28. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, et al. Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2008;21:1-10.
29. Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, et al. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 2009;276:3881-93.
30. Muller KM, Arndt KM, Strittmatter W, Pluckthun A. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 1998;422:259-64.
31. Carrel S, Sordat B, Merenda C. Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice. Cancer Res 1976;36:3978-84.
32. Leconte A, Garambois V, Ychou M, Robert B, Pourquier D, Terskikh A, et al. Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model. Br J Cancer 1999;80:1373-9.
33. Mizobata S, Tompkins K, Simpson JF, Shyr Y, Primus FJ. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol Immunother 2000;49: 285-95.
34. Vivier E, Rochet N, Ackerly M, Petrini J, Levine H, Daley J, et al. Signaling function of reconstituted CD16: Zeta: Gamma receptor complex isoforms. Int Immunol 1992;4:1313-23.
35. Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci U S A 1982;79: 3275-9.
36. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003;277:185-92.
37. Sack TL, Gum JR, Low MG, Kim YS. Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol-specific phospholipase C. J Clin Invest 1988;82:586-93.
38. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting cerbB-2 and Fc gamma RIII. Cancer Res 1995;55:4586-93.
39. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997;89:2042-7.
40. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett 1998;425:479-84.
41. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69:4941-4.
42. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008;68:8049-57.
43. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, et al. Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 2011; 373:67-78.
44. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 2011;13:R123.
45. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012;188:1551-8.
46. Booth SN, King JP, Leonard JC, Dykes PW. Serum carcinoembryonic antigen in clinical disorders. Gut 1973;14:794-9.
47. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anticarcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-70.
48. Juweid ME, Hajjar G, Swayne LC, Sharkey RM, Suleiman S, Herskovic T, et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999;85: 1828-42.
49. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986;46:3969-78.
50. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008;21:283-8.
51. Tijink BM, Laeremans T,Budde M, Stigter-vanWalsumM,Dreier T, de Haard HJ, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: Taking advantage of modular Nanobody technology. Mol Cancer Ther 2008;7: 2288-97.